Local epicardial inotropic drug delivery allows targeted pharmacologic intervention with preservation of myocardial loading conditions

Journal of Pharmaceutical Sciences

Volumn 100, Issue 11, 2011, Pages 4993-5006

  Lovich, Mark A ^a,b   Wei, Abraham E ^a,b   Maslov, Mikhail Y ^a   Wu, Peter I ^b   Edelman, Elazer R ^b  

^a ST ELIZABETH'S MEDICAL CENTER   (United States)

^b MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

Author keywords

Alginate; Controlled release; Dobutamine; Epicardial; Heart failure; Inotrope; Local drug delivery; Myocardial contraction; Pharmacodynamics; Pharmacokinetics

Indexed keywords

DOBUTAMINE;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED RELEASE FORMULATION; CONTROLLED STUDY; DOSE RESPONSE; DRUG CONCENTRATION; DRUG DELIVERY SYSTEM; DRUG DOSE ESCALATION; DRUG EFFECT; DRUG MEGADOSE; EPICARDIAL RELEASE; EPICARDIUM; HEART CONTRACTION; HEART FUNCTION; HEART LEFT VENTRICLE; HEART MUSCLE CONTRACTILITY; HEART RATE; HEART STROKE VOLUME; HEART WORK; IN VITRO STUDY; IN VIVO STUDY; MALE; MEAN ARTERIAL PRESSURE; NONHUMAN; PHARMACODYNAMICS; PHARMACOKINETICS; RAT; SINGLE DRUG DOSE; SYSTEMIC VASCULAR RESISTANCE; SYSTOLIC BLOOD PRESSURE; VASCULARIZATION; VASODILATATION;

EID: 80053282660     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.22681     Document Type: Article

References (46)

1. Mak M, Fung L, Strasser JF, Saltzman WM. 1995. Distribution of drugs following controlled delivery to the brain interstitium. J Neurooncol 26(2):91-102.
2. Le KN, Hwang CW, Tzafriri AR, Lovich MA, Hayward A, Edelman ER. 2009. Vascular regeneration by local growth factor release is self-limited by microvascular clearance. Circulation 119(22):2928-2935.
3. Zamah AM, Delahunty M, Luttrell LM, Lefkowitz RJ. 2002. Protein kinase A-mediated phosphorylation of the beta 2-adrenergic receptor regulates its coupling to Gs and Gi. Demonstration in a reconstituted system. J Biol Chem 277(34):31249-31256.
4. Chen-Izu Y, Xiao RP, Izu LT, Cheng H, Kuschel M, Spurgeon H, Lakatta EG. 2000. G(i)-dependent localization of beta(2)-adrenergic receptor signaling to L-type Ca(2+) channels. Biophys J 79(5):2547-2556.
5. Minneman KP, Hegstrand LR, Molinoff PB. 1979. Simultaneous determination of beta-1 and beta-2-adrenergic receptors in tissues containing both receptor subtypes. Mol Pharmacol 16(1):34-46.
6. Pacher P, Mabley JG, Liaudet L, Evgenov OV, Marton A, Hasko G, Kollai M, Szabo C. 2004. Left ventricular pressure-volume relationship in a rat model of advanced aging-associated heart failure. Am J Physiol Heart Circ Physiol 287(5):H2132-H2137.
7. Pacher P, Nagayama T, Mukhopadhyay P, Batkai S, Kass DA. 2008. Measurement of cardiac function using pressure-volume conductance catheter technique in mice and rats. Nat Protoc 3(9):1422-1434.
8. Edelman ER, Mathiowitz E, Langer R, Klagsbrun M. 1991. Controlled and modulated release of basic fibroblast growth factor. Biomaterials 12(7):619-626.
9. Skjak-Braek G, Grasdalen H, Smidsrod O. 1989. Inhomogeneous polysaccharide ionic gels. Carbohydr Polym 10:31-54.
10. LeRoux MA, Guilak F, Setton LA. 1999. Compressive and shear properties of alginate gel: Effects of sodium ions and alginate concentration. J Biomed Mater Res 47(1):46-53.
11. El-Kommos ME, Mohamed FA, Khedr AS. 1990. Spectrophotometric determination of some catecholamine drugs using metaperiodate. J Assoc Off Anal Chem 73(4):516-520.
12. Pacher P, Batkai S, Osei-Hyiaman D, Offertaler L, Liu J, Harvey-White J, Brassai A, Jarai Z, Cravatt BF, Kunos G. 2005. Hemodynamic profile, responsiveness to anandamide, and baroreflex sensitivity of mice lacking fatty acid amide hydrolase. Am J Physiol Heart Circ Physiol 289(2):H533-H541.
13. Pacher P, Liaudet L, Bai P, Mabley JG, Kaminski PM, Virag L, Deb A, Szabo E, Ungvari Z, Wolin MS, Groves JT, Szabo C. 2003. Potent metalloporphyrin peroxynitrite decomposition catalyst protects against the development of doxorubicin-induced cardiac dysfunction. Circulation 107(6):896-904.
14. Pacher P, Liaudet L, Soriano FG, Mabley JG, Szabo E, Szabo C. 2002. The role of poly(ADP-ribose) polymerase activation in the development of myocardial and endothelial dysfunction in diabetes. Diabetes 51(2):514-521.
15. Knudsen JD, Frimodt-Moller N, Espersen F. 1995. Experimental Streptococcus pneumoniae infection in mice for studying correlation of in vitro and in vivo activities of penicillin against pneumococci with various susceptibilities to penicillin. Antimicrob Agents Chemother 39(6):1253-1258.
16. Norenberg W, Hempel C, Urban N, Sobottka H, Illes P, Schaefer M. 2011. Clemastine potentiates the human P2×7 receptor by sensitizing it to lower ATP concentrations. J Biol Chem 286(13):11067-11081.
17. Rodriguez CA, Agudelo M, Zuluaga AF, Vesga O. 2010. In vitro and in vivo comparison of the anti-staphylococcal efficacy of generic products and the innovator of oxacillin. BMC Infect Dis 10:153.
18. Belz GG, Breithaupt-Grogler K, Butzer R, Fuchs W, Hausdorf C, Mang C. 2000. The pharmacological potency of various AT(1) antagonists assessed by Schild regression technique in man. J Renin Angiotensin Aldosterone Syst 1(4):336-341.
19. Evans MA, Shanks CA, Brown KF, Triggs EJ. 1984. Pharmacokinetic and pharmacodynamic modelling with pancuronium. Eur J Clin Pharmacol 26(2):243-250.
20. Hockings N, Ajayi AA, Reid JL. 1986. Age and the pharmacokinetics of angiotensin converting enzyme inhibitors enalapril and enalaprilat. Br J Clin Pharmacol 21(4):341-348.
21. Sagawa K, Suga H, Shoukas AA, Bakalar KM. 1977. End-systolic pressure/volume ratio: A new index of ventricular contractility. Am J Cardiol 40(5):748-753.
22. Merillon JP, Neukirch F, Motte G, Aumont MC, Curien ND, Prasquier R, Gourgon R. 1981. The left ventricular end-systolic pressure-volume ratio. Studies during changes in load and inotropism in the human. Eur Heart J 2(1):41-48.
23. Burnam MH, Sethna DH, Rose DM, Stern CS, Shell WE. 1981. Differences in beta-adrenoceptor binding in anterior and inferior myocardial wall microsomes of normal canine left ventricle. Cardiovasc Res 15(4):239-244.
24. Lovich MA, Edelman ER. 1999. Tissue concentration of heparin, not administered dose, correlates with the biological response of injured arteries in vivo. Proc Natl Acad Sci U S A 96(20):11111-11116.
25. Creel CJ, Lovich MA, Edelman ER. 2000. Arterial paclitaxel distribution and deposition. Circ Res 86(8):879-884.
26. Wu PI, Edelman ER. 2008. Structural biomechanics modulate intramuscular distribution of locally delivered drugs. J Biomech 41(13):2884-2891.
27. Wu PI, Minisini S, Edelman ER. 2009. Intramuscular drug transport under mechanical loading: Resonance between tissue function and uptake. J Control Release 136(2):99-109.
28. Shan K, Bick RJ, Poindexter BJ, Nagueh SF, Shimoni S, Verani MS, Keng F, Reardon MJ, Letsou GV, Howell JF, Zoghbi WA. 2000. Altered adrenergic receptor density in myocardial hibernation in humans: A possible mechanism of depressed myocardial function. Circulation 102(21):2599-2606.
29. Shan K, Bick RJ, Poindexter BJ, Shimoni S, Letsou GV, Reardon MJ, Howell JF, Zoghbi WA, Nagueh SF. 2000. Relation of tissue Doppler derived myocardial velocities to myocardial structure and beta-adrenergic receptor density in humans. J Am Coll Cardiol 36(3):891-896.
30. Yan M, Webster LT, Jr., Blumer JL. 2002. Kinetic interactions of dopamine and dobutamine with human catechol-O-methyltransferase and monoamine oxidase in vitro. J Pharmacol Exp Ther 301(1):315-321.
31. Yan M, Webster LT, Jr., Blumer JL. 2002. 3-O-methyldobutamine, a major metabolite of dobutamine in humans. Drug Metab Dispos 30(5):519-524.
32. Gennser G, Rosengren E, von Studnitz W. 1973. Distribution of noradrenaline and of monoamine oxidase and catechol-O-methyltransferase activity in human foetal heart. Experientia 29(1):20-22.
33. Krakoff LR, Buccino RA, Spann JF Jr., De Champlain J. 1968. Cardiac catechol O-methyltransferase and monoamine oxidase activity in congestive heart failure. Am J Physiol 215(3):549-552.
34. Ruffolo R, Jr., Morgan EL. 1984. Interaction of the enantiomers of 3-0-methyldobutamine, a metabolite of dobutamine, with alpha- and beta-adrenoreceptors in the cardiovascular system of the pithed rat. J Auton Pharmacol 4(4):295-302.
35. Alexander N, Velasquez M, Vlachakis ND. 1981. Red blood cells: In vivo site for transport and inactivation of biogenic amines in man and rats. Life Sci 29(5):477-482.
36. Alexander N, Yoneda S, Vlachakis ND, Maronde RF. 1984. Role of conjugation and red blood cells for inactivation of circulating catecholamines. Am J Physiol 247(1 Pt 2):R203-R207.
37. Yoneda S, Alexander N, Vlachakis ND, Maronde RF. 1984. Role of conjugation and red blood cells for inactivation of circulating normetanephrine. Am J Physiol 247(1 Pt 2):R208-R211.
38. Carrel T, Englberger L, Mohacsi P, Neidhart P, Schmidli J. 2000. Low systemic vascular resistance after cardiopulmonary bypass: Incidence, etiology, and clinical importance. J Card Surg 15(5):347-353.
39. Ruel M, Khan TA, Voisine P, Bianchi C, Sellke FW. 2004. Vasomotor dysfunction after cardiac surgery. Eur J Cardiothorac Surg 26(5):1002-1014.
40. Murphy GJ, Angelini GD. 2004. Side effects of cardiopulmonary bypass: What is the reality? J Card Surg 19(6):481-488.
41. St Andre AC, DelRossi A. 2005. Hemodynamic management of patients in the first 24 hours after cardiac surgery. Crit Care Med 33(9):2082-2093.
42. Laham RJ, Simons M, Hung D. 1999. Subxyphoid access of the normal pericardium: A novel drug delivery technique. Catheter Cardiovasc Interv 47(1):109-111.
43. Verrier RL, Waxman S, Lovett EG, Moreno R. 1998. Transatrial access to the normal pericardial space: A novel approach for diagnostic sampling, pericardiocentesis, and therapeutic interventions. Circulation 98(21):2331-2333.
44. Waxman S, Pulerwitz TC, Rowe KA, Quist WC, Verrier RL. 2000. Preclinical safety testing of percutaneous transatrial access to the normal pericardial space for local cardiac drug delivery and diagnostic sampling. Catheter Cardiovasc Interv 49(4):472-477.
45. Moreno R, Waxman S, Rowe K, Verrier RL. 2000. Intrapericardial beta-adrenergic blockade with esmolol exerts a potent antitachycardic effect without depressing contractility. J Cardiovasc Pharmacol 36(6):722-727.
46. Hou D, Rogers PI, Toleikis PM, Hunter W, March KL. 2000. Intrapericardial paclitaxel delivery inhibits neointimal proliferation and promotes arterial enlargement after porcine coronary overstretch. Circulation 102(13):1575-1581.